Why AAV Gene Therapy Innovation Must Align with Manufacturing Readiness

Adeno-associated virus has become one of the most established vector platforms in gene therapy, with approved products across multiple indications and a development pipeline that continues to expand in both breadth and technical ambition. As that pipeline matures, however, the challenge is no longer limited to improving biological performance through better tropism, greater immune evasion, or more sophisticated genome design. Increasingly, the question is whether these innovations can be translated into products that are sufficiently robust, scalable, and well understood to support clinical development and later manufacturing.

Why AAV Innovation Needs to Be Matched by Manufacturing and Analytical Readiness

Adeno-associated virus has become one of the most established vector platforms in gene therapy, with approved products across multiple indications and a development pipeline that continues to expand in both breadth and technical ambition. As that pipeline matures, however, the challenge is no longer limited to improving biological performance through better tropism, greater immune evasion, or more sophisticated genome design. Increasingly, the question is whether these innovations can be translated through AAV process development into products that are sufficiently robust, scalable, and well understood to support clinical development and later manufacturing. Recent advances in AAV design have undoubtedly widened therapeutic possibilities, but they have also made it harder to rely on assumptions that may have held true for more familiar vectors or platform processes.

This theme is explored in two recent trade articles by eXmoor Pharma subject matter experts. In BioProcess International, Clare Blue, Senior CMC Consultant, and Daphné Bocciarelli, Head of Viral Vector, argue that innovation, manufacturability, and product quality are tightly connected, and that decisions around capsid design, genome architecture, and platform selection can influence yield, product quality, and lifecycle risk far earlier than teams may expect. In European Pharmaceutical Review, Daphné Bocciarelli, Head of Viral Vector, develops this further, showing how novel vector designs can disrupt the historical predictability on which established manufacturing approaches often depend. Taken together, both articles point to a broader industry reality. AAV innovation does not simply create new therapeutic opportunity. It also reshapes the manufacturing and analytical conditions in which a product must perform.

How AAV Vector Design Impacts Manufacturing and Product Quality

One of the more important points to emerge from both articles is that vector design decisions do not remain confined to discovery. Capsid selection, genome structure, payload length, plasmid composition, and production platform all help determine how a programme behaves in production, what types of impurities may arise, and how easily product quality can be characterised and controlled. In practice, this means that development teams are not simply selecting a promising therapeutic candidate. They are also defining much of the complexity of the manufacturing challenge that follows. As Clare Blue notes in BioProcess International, “choices around capsid design, genome architecture, and platform selection influence product quality, yield, and lifecycle risk.”

This becomes especially relevant when programmes move beyond established AAV approaches. Engineered capsids may offer improved tropism or immune evasion, while self-complementary and dual-vector strategies can help address biological limitations such as payload capacity. Yet the same features that make these designs attractive may also make them harder to manufacture. Novel capsids may behave differently during purification, fail to interact with standard affinity reagents in the expected way, or show altered charge behaviour that complicates downstream processing. Likewise, changes in genome design may affect packaging efficiency, increase the proportion of empty or partial capsids, or introduce added complexity into potency and integrity testing.

Why Platform Assumptions Break in Novel AAV Development

In her European Pharmaceutical Review article, Daphné Bocciarelli argues that innovation challenges manufacturing assumptions because it alters the cause-and-effect relationships on which those assumptions are built. That observation is particularly relevant in AAV, where platform assumptions often rely on a degree of historical predictability around upstream productivity, impurity profile, purification behaviour, or final product characteristics. Once developers move into less familiar design space, that predictability can weaken. A process that appears sound on paper may not translate cleanly when a new capsid, alternative genome architecture, or more complex impurity profile changes the way the product behaves across development and manufacture.

As Daphné Bocciarelli writes in European Pharmaceutical Review:

“The consequences of early design choices often only become visible at later stages, when process changes are more difficult to implement.”

Daphné Bocciarelli

Head of Viral Vector

That challenge becomes more visible as programmes move from early design into AAV GMP manufacturing, where product complexity can expose weaknesses in process understanding or analytics. This does not mean that innovation should be restrained. It does, however, mean that novelty brings consequences that need to be understood in a more integrated way. In AAV development, manufacturing complexity is often not a separate downstream issue. It is a direct extension of the biology, the product design, and the platform choices made earlier in the programme.

Why Analytical Readiness Is Critical in AAV GMP Manufacturing

That is why analytical readiness becomes increasingly important as AAV products become more technically ambitious. In this setting, analytics do far more than confirm whether a batch meets specification. They support product understanding, guide process development, and provide the basis for comparability when changes are introduced. Where vector designs move away from well-characterised systems, legacy assays may no longer offer the specificity or sensitivity required, and more specialised or orthogonal methods may be needed to assess genome integrity, capsid composition, potency, or impurity burden with confidence. Clare Blue and Daphné Bocciarelli make this point clearly in BioProcess International, particularly in relation to engineered capsids, self-complementary AAV, and dual-vector approaches, all of which may require analytical strategies that go beyond standard platform methods.

Analytical maturity matters not only because it supports development efficiency, but because it reduces uncertainty. Where product understanding is limited, it becomes harder to troubleshoot effectively, harder to interpret variability, and harder to support process evolution without creating additional risk. In that sense, analytical readiness is not separate from manufacturing readiness. The two are closely linked.

Balancing Innovation and Manufacturability in AAV Gene Therapy

None of this suggests that more advanced AAV designs are inherently problematic, or that developers should default to more conventional routes wherever possible. The real challenge is not innovation itself, but whether its consequences are being understood clearly enough across development, analytics, and manufacturing. In AAV, trade-offs are unavoidable. Higher expression may not improve packaging fidelity. Improved purity may reduce yield. A vector design that performs well in proof-of-concept studies may prove more difficult to manufacture consistently at useful scale. These are familiar tensions in gene therapy development, but they are easier to manage when they are recognised as part of the product development challenge rather than treated as isolated process issues later on.

This has relevance across the full range of organisations now developing AAV therapies. Academic teams and early spin-outs may be focused on translational progress and first-in-human readiness, often with limited internal CMC resource. More established biotech companies may be more concerned with process robustness, technology transfer, and the ability to avoid disruption as programmes advance. Larger organisations tend to place greater emphasis on delivery confidence, analytical maturity, and whether a partner can support future manufacturing requirements without introducing unnecessary complexity. Those priorities differ, but the underlying issue is the same. In AAV, product innovation and manufacturing performance are closely connected, and decisions in one area quickly shape outcomes in the other.

As the field continues to evolve, the programmes most likely to progress effectively will be those that pair scientific ambition with a realistic understanding of manufacturing and analytical demands. AAV innovation remains an important driver of therapeutic progress, but the programmes that succeed will be the ones that are not only biologically promising, but also supported by the process understanding and analytical strategy needed to translate that promise into practice.

Explore how eXmoor Pharma supports AAV gene therapy process development, GMP manufacturing, and case studies through our AAV services.